%PDF-1.4
%
263 0 obj
<>/OCGs[280 0 R]>>/PageLabels 249 0 R/Pages 251 0 R/Type/Catalog>>
endobj
279 0 obj
<>/Font<>>>/Fields 284 0 R>>
endobj
260 0 obj
<>stream
Acrobat Distiller 6.0.1 (Windows)
2008-11-27T09:23:46+01:00
2010-11-08T18:14:38+01:00
2010-11-08T18:14:38+01:00
uuid:e9b1bf3f-493e-4ed4-b3cb-f564c603de8f
uuid:2d35da02-c30c-4a75-b55b-fbd138b09e56
application/pdf
untitled
endstream
endobj
249 0 obj
<>
endobj
251 0 obj
<>
endobj
252 0 obj
<>
endobj
253 0 obj
<>
endobj
254 0 obj
<>
endobj
255 0 obj
<>
endobj
256 0 obj
<>
endobj
257 0 obj
<>
endobj
258 0 obj
<>
endobj
259 0 obj
<>
endobj
213 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
216 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
219 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
222 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
225 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
297 0 obj
<>stream
q
0.9259491 0 0 0.9259491 16.0982208 56.695816 cm
0 0 595 842 re
W n
1.079973 0 0 1.079973 -17.3856434 -61.2299491 cm
BT
/GS0 gs
/TT0 1 Tf
0.0004 Tc -0.0028 Tw 9.2781 0 0 9.2781 362.7202 794.9045 Tm
[(Eviden)6(zb)6(asi)7(e)6(rte Leitlinie d)6(er DDG)6( )]TJ
-0.0014 Tc -0.001 Tw 3.27 -1.144 Td
[(Update v)-4(o)-2(m Ok)-4(tober 2008 )]TJ
/TT1 1 Tf
0 Tc 0 Tw 11.1115 0 0 11.1115 81.767 771.9593 Tm
( )Tj
18.6222 Tc 0 -61.22 TD
( )Tj
0.0007 Tc 9.2781 0 0 9.2781 491.5019 91.7157 Tm
[(75)6( )]TJ
/TT2 1 Tf
-0.0001 Tc 0.0023 Tw 11.1115 0 0 11.1115 81.767 759.1256 Tm
(4.6 Literatur )Tj
/TT1 1 Tf
0 Tc 0 Tw 10.167 0 0 10.167 81.767 747.2363 Tm
( )Tj
0.0006 Tc 0.0003 Tw 0 -1.153 TD
[(1. UK Prospective Diabetes Study \(UKPDS\) )-5(Gr)]TJ
0.001 Tc -0.0001 Tw 20.874 0 Td
[(ou)-6(p: Intensive blood-gluco)5(s)-2(e control with )]TJ
-20.874 -1.153 Td
[(sulfonylureas or insulin compared wit)-5(h conventional treatment and risk of )6(complication)5(s)-2( in )]TJ
T*
[(patients with)5( type-2 diabetes. \(UKPDS 33\). Lancet \(1998\) 352: 837-853 )]TJ
0 Tc 0 Tw 0 -1.147 TD
( )Tj
0.0009 Tc 0 -1.153 TD
[(2. Shichiri M, Kishikawa )6(H, Ohkubo Y, Wake N: Long-term results of the)5( Kuma)-6(moto Study on )]TJ
0.0011 Tc -0.0002 Tw T*
[(optimal diabetes control )6(in type 2 diabetic patient)6(s. Diabetes )6(Care \(2000\) 23 \(Suppl.2\): B21-)]TJ
0.0008 Tc 0.0001 Tw T*
(B29 )Tj
0 Tc 0 Tw T*
( )Tj
0.0009 Tc 0 -1.147 TD
[(3. The Actio)5(n to Control Cardiovascular Risk in D)7(i)-1(abetes Stud)5(y Group: Eff)-5(ect of Intensive )]TJ
0.001 Tc -0.0001 Tw 0 -1.153 TD
[(Glucose Lo)5(wering in Type 2 Diabetes. N Eng J Med \(2008\) 358:2545-2559 )]TJ
0 Tc 0 Tw T*
( )Tj
0.0009 Tc T*
[(4. The ADVANCE )-5(Collaborative Gro)-6(up: Intensive Blood Glucose Contro)5(l and Vascular )]TJ
0.001 Tc -0.0001 Tw T*
(Outcomes in Patients with Type 2 Diabetes. N Eng J Med \(2008\) 358:2560\
-2572 )Tj
0 Tc 0 Tw T*
( )Tj
0.0008 Tc 0.0001 Tw 0 -1.147 TD
[(5. Patel A , The ADVANCE Collaborative Group,)-5( McMahon )-5(S et al.: Effect of a fixed )]TJ
0.0012 Tc -0.0003 Tw 0 -1.153 TD
[(combination of perindop)5(ril and indap)5(amide on macrovascula)5(r and microvascular out)6(comes in )]TJ
0.001 Tc -0.0001 Tw T*
[(patients with)5( type 2 diabetes mellitus. Lancet \(20)5(07\) 370:829-840 )]TJ
0 Tc 0 Tw T*
( )Tj
0.0005 Tc 0.0004 Tw T*
[(6. Dluhy RG and McMah)-6(on GT: Intensive Glyc)]TJ
0.001 Tc -0.0001 Tw 20.596 0 Td
[(emic Control in )6(the ACCORD and ADVANCE )]TJ
-20.596 -1.147 Td
(Trials. N Eng J Med \(2008\) 358:2630-2633 )Tj
0 Tc 0 Tw T*
( )Tj
0.0007 Tc 0.0002 Tw T*
[(7. UKPDS )-5(Group: Effect of intensive blood-gluc)]TJ
0.0012 Tc -0.0003 Tw 20.989 0 Td
[(ose control )6(with metformin on complication)5(s)-1( )]TJ
0.0009 Tc 0 Tw -20.989 -1.153 Td
[(in overweight patients )6(with type 2 diabetes \(U)7(KPDS 34\) L)-6(ancet 352 \(1)5(998\) 854-865 )]TJ
0 Tc T*
( )Tj
0 -1.147 TD
( )Tj
ET
/Artifact <>BDC
Q
q
1 0 0 1 87.8280029 77.4095612 cm
/GS1 gs
/Fm0 Do
Q
EMC
endstream
endobj
299 0 obj
<>>>/Resources 302 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/Arial 8 Tf
0 g
0 -6.316 Td
(Die ) Tj
14.227 0 Td
("Leitlinien" ) Tj
39.48 0 Td
(der ) Tj
13.785 0 Td
(Wissenschaftlichen ) Tj
70.696 0 Td
(Medizinischen ) Tj
52.914 0 Td
(Fachgesellschaften ) Tj
71.152 0 Td
(sind ) Tj
16.898 0 Td
(systematisch ) Tj
48.457 0 Td
(entwickelte ) Tj
-327.609 -9.6 Td
(Hilfen ) Tj
22.676 0 Td
(f\374r ) Tj
11.558 0 Td
(\304rzte ) Tj
20.895 0 Td
(zur ) Tj
13.336 0 Td
(Entscheidungsfindung ) Tj
80.949 0 Td
(in ) Tj
8.449 0 Td
(spezifischen ) Tj
46.246 0 Td
(Situationen. ) Tj
44.477 0 Td
(Sie ) Tj
13.785 0 Td
(beruhen ) Tj
31.582 0 Td
(auf ) Tj
13.344 0 Td
(aktuellen ) Tj
34.246 0 Td
(wissenschaftlichen ) Tj
-341.543 -9.6 Td
(Erkenntnissen ) Tj
52.918 0 Td
(und ) Tj
15.57 0 Td
(in ) Tj
8.45 0 Td
(der ) Tj
13.785 0 Td
(Praxis ) Tj
24.449 0 Td
(bew\344hrten ) Tj
39.582 0 Td
(Verfahren ) Tj
37.355 0 Td
(und ) Tj
15.571 0 Td
(sorgen ) Tj
26.683 0 Td
(f\374r ) Tj
11.559 0 Td
(mehr ) Tj
20.449 0 Td
(Sicherheit ) Tj
37.797 0 Td
(in ) Tj
8.449 0 Td
(der ) Tj
13.785 0 Td
(Medizin, ) Tj
32.012 0 Td
(sollten ) Tj
25.348 0 Td
(aber ) Tj
18.234 0 Td
(auch ) Tj
-401.996 -9.6 Td
(\366konomische ) Tj
49.359 0 Td
(Aspekte ) Tj
31.129 0 Td
(ber\374cksichtigen. ) Tj
60.032 0 Td
(Die ) Tj
14.226 0 Td
("Leitlinien" ) Tj
39.481 0 Td
(sind ) Tj
16.898 0 Td
(f\374r ) Tj
11.559 0 Td
(\304rzte ) Tj
20.894 0 Td
(rechtlich ) Tj
32.012 0 Td
(nicht ) Tj
19.121 0 Td
(bindend ) Tj
30.695 0 Td
(und ) Tj
15.571 0 Td
(haben ) Tj
24.468 0 Td
(daher ) Tj
22.684 0 Td
(weder ) Tj
-388.129 -9.6 Td
(haftungsbegr\374ndende ) Tj
80.07 0 Td
(noch ) Tj
19.571 0 Td
(haftungsbefreiende ) Tj
70.722 0 Td
(Wirkung. ) Tj
-170.363 -9.6 Td
( ) Tj
0 -9.6 Td
(Die ) Tj
14.227 0 Td
(AWMF ) Tj
26.66 0 Td
(erfasst ) Tj
26.23 0 Td
(und ) Tj
15.571 0 Td
(publiziert ) Tj
34.238 0 Td
(die ) Tj
12.898 0 Td
(Leitlinien ) Tj
33.801 0 Td
(der ) Tj
13.785 0 Td
(Fachgesellschaften ) Tj
71.153 0 Td
(mit ) Tj
12.886 0 Td
(gr\366\337tm\366glicher ) Tj
55.574 0 Td
(Sorgfalt ) Tj
29.793 0 Td
(- ) Tj
4.887 0 Td
(dennoch ) Tj
32.918 0 Td
(kann ) Tj
19.57 0 Td
(die ) Tj
-404.191 -9.6 Td
(AWMF ) Tj
26.66 0 Td
(f\374r ) Tj
11.559 0 Td
(die ) Tj
12.898 0 Td
(Richtigkeit ) Tj
39.125 0 Td
(- ) Tj
4.887 0 Td
(insbesondere ) Tj
50.258 0 Td
(von ) Tj
15.121 0 Td
(Dosierungsangaben ) Tj
73.832 0 Td
(- ) Tj
4.887 0 Td
(keine ) Tj
21.347 0 Td
(Verantwortung ) Tj
54.254 0 Td
(\374bernehmen. ) Tj
ET
endstream
endobj
300 0 obj
<>
endobj
302 0 obj
<>
endobj
303 0 obj
<>
endobj
304 0 obj
<>
endobj
305 0 obj
<>
endobj
306 0 obj
<>stream
HԖiTY_e#0l
X KmvaXa5!ltH+Iˢ"V@PTPFTd7lqA[QQP
f<ީz{zW@
n/O] VǶɝ^ hk Ig(t z`. >"A :>Aծ>Aӛ\Eu.@e t z~"! grS/DbYI dSMLBCʐ(nJ5@!fE
`b2w +J ЏZ "< XLY4\H@L.+Er
;&]z2ō z c?I%S=W%F}- yd
4e#ڀj`iqa"ku$CJS
(X5YF-Û $ L)MYHe:$0A$H|d֝v֩c+6.=~ﵤT`T` })PppQ4~>LWI@1q`AUϕ/HrbDd#1bkK#rB~?FDvi,ϣKe~ƿ|ArD:іS(0LNI R@B5
؏iI(i^ed3 \R_lٟEʗnkKHvx~Zx,$nYqikzl
Ml+{2U$1U#I?4KyV\e_B'Q
ԤUûL48kRmZ`dh֍`mvσ
OWqE~݅
F g&79\_X8(GxP?`)ٮC|eepSB}V/B%+G0҃.'쮜N'cB.x>:3c]}6>eTI8i:F#rSQC*
A)E5